欧洲药品管理局对缬沙坦中活性物质进行评估

2018-07-27 14:34:23.0

欧洲药品质量管理局认识到一起在欧洲市场颉沙坦中活性杂质被用来治疗高血压引起药品质量缺陷。早在本月初,欧洲药品管理局就启动了全欧洲的警戒系统以评估该颉沙坦事件的范围和影响,进而建立矫正措施。


EDQM’s actions to evaluate impact of impurity in active substance valsartan

2018-07-27 14:34:23.0

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is aware of a quality defect related to an impurity in the active substance valsartan used in medicines to treat high blood pressure marketed in Europe.